Evacetrapib Appears Futile in High-Risk Vascular Disease

Share this content:
Evacetrapib Appears Futile in High-Risk Vascular Disease
Evacetrapib Appears Futile in High-Risk Vascular Disease

WEDNESDAY, May 31, 2017 (HealthDay News) -- For patients with high-risk vascular disease, evacetrapib does not affect the primary efficacy end point of first occurrence of any component of a composite of death from cardiovascular causes, myocardial infarction, stroke, coronary revascularization, or hospitalization for unstable angina, according to a study published in the May 18 issue of the New England Journal of Medicine.

A. Michael Lincoff, M.D., from the Cleveland Clinic, and colleagues enrolled 12,092 patients with high-risk vascular disease. Participants were randomized to receive evacetrapib or matching placebo daily, as well as standard medical therapy.

The researchers observed a 31.1 percent decrease in the mean low-density lipoprotein cholesterol level with evacetrapib versus a 6.0 percent increase with placebo at three months; 133.2 and 1.6 percent increases were seen in the mean high-density lipoprotein cholesterol levels with evacetrapib and placebo, respectively. The trial was terminated early due to lack of efficacy after 1,363 of the planned 1,670 primary end-point events had occurred. A primary end point occurred in 12.9 and 12.8 percent of patients in the evacetrapib and placebo groups, respectively, after a median of 26 months (hazard ratio, 1.01; 95 percent confidence interval, 0.91 to 1.11; P = 0.91)

"Although the cholesteryl ester transfer protein inhibitor evacetrapib had favorable effects on established lipid biomarkers, treatment with evacetrapib did not result in a lower rate of cardiovascular events than placebo among patients with high-risk vascular disease," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Eli Lilly, which manufactures evacetrapib and funded the study.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

NAFLD Linked to Smaller Total Cerebral Brain Volume

NAFLD Linked to Smaller Total Cerebral Brain Volume

Significant correlation even after adjustment for all covariates, including age, sex, alcohol consumption

Salivary miRNAs Can ID Duration of Concussion Symptoms

Salivary miRNAs Can ID Duration of Concussion Symptoms

Pediatric patients with prolonged symptoms were accurately identified by levels of five miRNAs

Treatment Trajectories Vary for Children With Depression

Treatment Trajectories Vary for Children With Depression

Most common class got psychotherapy monotherapy, and had lowest incidence of attempted suicide

is free, fast, and customized just for you!

Already a member?

Sign In Now »